Anti-inflammatory and Antipyretic Granules segmentation by type distinguishes three chemical families that together explain the market’s structural dynamics. The first family, non‑steroidal anti‑inflammatory drug (NSAID) granules, includes ibuprofen, naproxen, and diclofenac derivatives; these agents dominate the segment with an estimated 55 % contribution, reflecting their broad therapeutic index, established safety profile, and extensive use in both acute and chronic indications. The second family, acetaminophen‑based granules, captures formulations that primarily exert antipyretic effects while offering modest anti‑inflammatory activity; this group accounts for roughly 30 % of sales, driven by consumer preference for milder gastrointestinal impact and widespread OTC availability. The third family, herbal and phytochemical granules, comprises extracts such as willow bark, curcumin, and Boswellia; despite a smaller 15 % market share, this niche is expanding as clinicians and patients seek natural adjuncts with lower systemic risk. Each type contributes distinct pricing, regulatory, and distribution characteristics that shape the overall market size and forecasted growth trajectory, underscoring the importance of a nuanced market taxonomy.
